Sign In
Buy NVAX
$10.19
-0.0100 (-0.0980%)
At Close: Jun 04, 2026
Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates
12:55am, Thursday, 05'th May 2022 Zacks Investment Research
Ligand (LGND) delivered earnings and revenue surprises of -4.92% and 33.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
What's Happening With Novavax Stock?
11:00am, Wednesday, 04'th May 2022
Covid-19 vaccine developer Novavax's stock (NASDAQ: NVAX) has had a rough 2022 so far, remaining down by almost 60% year-to-date.
Why Is Novavax Stock Rising This Week?
09:57am, Wednesday, 04'th May 2022
The quarterly results and FDA approval for EUA could push NVAX stock higher in the coming weeks, so take your position now. The post Why Is Novavax Stock Rising This Week?
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
05:15pm, Tuesday, 03'rd May 2022 Zacks Investment Research
On Novavax's (NVAX) first-quarter earnings call, investor focus is likely to be on the sales figures of its COVID-19 vaccine.
BioNTech (BNTX) to Report Q1 Earnings: What's in the Cards?
03:22pm, Tuesday, 03'rd May 2022 Zacks Investment Research
On BioNTech's (BNTX) first-quarter earnings call, investors' focus is expected to be on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.
Novavax (NVAX) Surges 19.3%: Is This an Indication of Further Gains?
10:40am, Tuesday, 03'rd May 2022 Zacks Investment Research
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength do
Novavax (NVAX) Surges 19.3%: Is This an Indication of Further Gains?
08:17am, Tuesday, 03'rd May 2022
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength do
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
07:21pm, Monday, 02'nd May 2022 Zacks Investment Research
On Vertex Pharmaceuticals' (VRTX) Q1 earnings call, investors are most likely to focus on the sales performance of its triple combo CF drug Trikafta/Kaftrio and updates on the non-CF pipeline.
Novavax (NVAX) to Report Q1 Results: Wall Street Expects Earnings Growth
07:00pm, Monday, 02'nd May 2022 Zacks Investment Research
Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Novavax Stock Is Soaring Today
03:56pm, Monday, 02'nd May 2022 The Motley Fool
Investors remain optimistic about an upcoming FDA advisory committee meeting.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
03:10pm, Monday, 02'nd May 2022 Zacks Investment Research
Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.
San Francisco–area transit system reinstates face-mask mandate, and FDA committee is set to review Novavax vaccine in June
12:24pm, Monday, 02'nd May 2022 MarketWatch
San Francisco's Bay Area Rapid Transit system is reinstating a face-mask mandate for riders, making it the only big transit system in the region to do so, as it moves to protect at-risk individuals in
Why Novavax Stock Is Soaring Today
11:56am, Monday, 02'nd May 2022
Investors remain optimistic about an upcoming FDA advisory committee meeting.
Novavax (NVAX) Gains As Market Dips: What You Should Know
09:45pm, Friday, 29'th Apr 2022 Zacks Investment Research
Novavax (NVAX) closed the most recent trading day at $45.07, moving +1.81% from the previous trading session.
San Francisco–area transit system reinstates face-mask mandate, and FDA committee is set to review Novavax vaccine in June
05:28pm, Friday, 29'th Apr 2022 MarketWatch
San Francisco's Bay Area Rapid Transit system is reinstating a face-mask mandate for riders, making it the only big transit system in the region to do so, as it moves to protect at-risk individuals in
